Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Last updated: June 25, 2024
Sponsor: Regeneron Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

Macular Edema

Geographic Atrophy

Macular Degeneration

Treatment

aflibercept 8 mg PFS

Clinical Study ID

NCT05989126
VGFTe-HD-OD-22105
  • Ages > 18
  • All Genders

Study Summary

Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial.

This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD).

The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. Patient must have diabetic macular edema (DME) or neovascular "wet" age-relatedmacular degeneration (nAMD) in the study eye

  2. Study eye considered by the retina specialist to be eligible for treatment with 8 mgaflibercept

Exclusion

Key Exclusion Criteria:

  1. Any active intraocular inflammation or infection in either eye or history ofintraocular inflammation or infection after past IVT injections with any agent ineither eye

  2. Treatment with any IVT injection in the study eye within the 25 days prior to day 1

  3. Intraocular pressure (IOP) >25 mm Hg in the study eye at screening

  4. Any intraocular surgery in the study eye at any time during the past 3 months

  5. Any prior extended-release therapeutic agent, or ocular drug-release deviceimplantation (approved or investigational, including steroids) in the study eye

NOTE: Other protocol Defined Inclusion/Exclusion Criteria Apply

Study Design

Total Participants: 35
Treatment Group(s): 1
Primary Treatment: aflibercept 8 mg PFS
Phase: 3
Study Start date:
April 15, 2024
Estimated Completion Date:
May 31, 2024

Connect with a study center

  • Retina Consultants of Texas

    Bellaire, Texas 77401
    United States

    Site Not Available

  • Retina Consultants of Texas

    The Woodlands, Texas 77385
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.